What it is
Methylene blue is a synthetic phenothiazine dye (C₁₆H₁₈ClN₃S, MW 319.85 g/mol, CAS 61-73-4, PubChem CID 6099). It was synthesized by Heinrich Caro at BASF in 1876, used by Paul Ehrlich and Paul Guttmann as the first synthetic antimalarial in 1891, and served as the lead compound for the phenothiazine antipsychotic class (chlorpromazine, promethazine) in the mid-20th century. In solution it exists in a redox equilibrium between an oxidized cation (MT⁺, blue, the tau-aggregation-inhibiting species per Wischik 2015) and a reduced leuco form (LMT, colorless). The cation is concentrated inside mitochondria along the membrane potential gradient where it can shuttle electrons from NADH to cytochrome c, effectively bypassing Complexes I and III. It is FDA-approved as an IV injection (Provayblue, 50 mg/10 mL) for acquired methemoglobinemia. The oral tablet formulation (Urolene Blue) has been discontinued in the US; compounded and 'research-use' oral preparations sold through wellness channels are not FDA-approved and were the subject of a September 18, 2025 FDA Consumer Update.
In plain English
Methylene blue is a lab-made blue dye — not a peptide. It was first made in 1876 at the German chemical company BASF. It was also the world's first synthetic antimalarial drug (1891) and the ancestor of a whole family of antipsychotic medications like chlorpromazine. In solution it switches back and forth between a blue form and a colorless form depending on whether it has picked up extra electrons. The blue form is pulled into mitochondria (the cell's power plants) by their natural charge gradient. Once inside, it can carry electrons from one part of the energy-making chain to another, skipping past two of the usual steps. It is FDA-approved only as an IV injection (Provayblue, 50 mg in 10 mL) for a specific blood condition. The old oral tablets (Urolene Blue) are no longer sold in the U.S. The over-the-counter drops and capsules sold online as "research chemicals" are not FDA-approved and were the target of the FDA's September 18, 2025 consumer warning.
How it works
- 01
Direct methemoglobin reduction (the approved mechanism)
In acquired methemoglobinemia, iron in the heme group is oxidized from Fe²⁺ to Fe³⁺, yielding methemoglobin that cannot carry oxygen. Methylene blue is reduced to leucomethylene blue by the erythrocyte enzyme NADPH-methemoglobin reductase (diaphorase), and leucomethylene blue then donates an electron to methemoglobin, restoring functional hemoglobin (Wright 1999; Clifton & Leikin 2003). Clinical response is visible within 30 minutes of a 1–2 mg/kg IV dose. This is the mechanism that underwrites the FDA approval.
In plain English
How it works for the one FDA-approved use: it resets damaged hemoglobin
In methemoglobinemia, the iron in hemoglobin (the oxygen-carrying part of red blood cells) gets stuck in the wrong form and can't pick up oxygen. Methylene blue hands that stuck iron a fresh electron, flipping it back to the working form. The patient gets oxygen-carrying blood back within 30 minutes of a 1–2 mg/kg IV dose. This simple, direct biochemistry is why the FDA approved it.
- 02
Alternative mitochondrial electron carrier
At low concentrations (≈100 nM–1 µM in target tissue), methylene blue accepts electrons from NADH and donates them to cytochrome c, bypassing Complex I and Complex III of the electron transport chain (Atamna 2008, FASEB J; Tucker 2018, Mol Neurobiol). This reroute increases Complex IV activity, has been reported to raise cellular ATP by 30–40% in cultured cells, and reduces electron leak and reactive-oxygen-species generation. The effect is hormetic: higher concentrations (>10 µM) reverse the benefit and generate oxidative stress. This mechanism is the basis of the cognitive, neuroprotective, and anti-aging hypotheses — it is well-characterized biochemically but has not translated to a Phase 3 signal outside of methemoglobinemia.
In plain English
It acts as a backup shuttle in the cell's power plant — with a "just right" dose window
At low levels inside tissue, methylene blue picks up electrons and hands them directly to a late step in the mitochondrial energy-making chain — skipping two earlier steps that can get clogged. In cultured cells, this has been shown to boost ATP (cell energy) by 30–40% and to cut down on harmful byproducts. But the dose window is narrow: too much (over 10 µM) flips the effect and actually causes damage. This is the biology that all the cognition, brain-protection, and anti-aging claims are built on. The biochemistry is real and interesting — but it has never produced a successful large human trial outside of methemoglobinemia.
- 03
Tau aggregation inhibition
The MT⁺ cation (not the reduced leuco form) binds and destabilizes paired helical filaments of tau, the neurofibrillary-tangle constituent of Alzheimer's disease (Wischik 1996; Baddeley 2015, J Pharmacol Exp Ther). Congdon 2012 showed that oral methylene blue in P301L tau transgenic mice reduced detergent-insoluble phospho-tau. This mechanism drove the TauRx development program (LMTX / TRx0237 / hydromethylthionine mesylate). Two Phase 3 RCTs — Gauthier 2016 (n=891 mild-moderate AD) and Wilcock 2018 (n=800 mild AD) — failed on primary cognitive and functional endpoints when used as add-on therapy; a post-hoc monotherapy subgroup signal did not survive prospective re-testing in LUCIDITY (2023). Necula 2007 separately showed that methylene blue inhibits fibrillar but not oligomeric amyloid-β, which may help explain the clinical-trial failure.
In plain English
It breaks up a protein tangle seen in Alzheimer's — but this didn't translate to patient benefit
Tau is a protein that forms the "tangles" in Alzheimer's brain tissue. The blue form of methylene blue sticks to these tangles and breaks them apart. A 2012 mouse study showed it reduced the bad form of tau. This is the biology that drove the big TauRx drug-development program. But two large Phase 3 trials (891 patients in 2016, 800 in 2018) both failed their main goals. A subgroup analysis that looked promising afterward did NOT hold up when tested properly in the 2023 LUCIDITY trial. A separate 2007 study noticed methylene blue may push the wrong-shaped proteins into the wrong size clumps — which may be part of why the trials failed.
- 04
Mitophagy induction and cerebral ischemia
Jiang 2015 (Mol Med) demonstrated that methylene blue attenuates acute cerebral ischemic injury in rats through induction of Parkin-dependent mitophagy, selectively clearing damaged mitochondria in the penumbra. Shen 2013 showed preservation of mitochondrial membrane potential and reduced apoptotic cell death in hippocampal CA1 after global ischemia. Zhao 2016 extended the model to traumatic brain injury. The rodent data is consistent across labs; no human efficacy trial in stroke or TBI has been completed.
In plain English
In rat stroke models, it helps clear damaged mitochondria — but no human trial yet
In rat stroke and head-injury experiments, methylene blue triggers the cell's "take out the trash" system (mitophagy) to selectively clear damaged mitochondria. Multiple independent rat studies (2013, 2015, 2016) show the same protective effect on brain cells. No human trial of stroke or head-injury outcomes has been completed.
- 05
MAO inhibition (the serotonin-syndrome mechanism)
Methylene blue is a potent inhibitor of monoamine oxidase A at clinically relevant plasma concentrations — IC₅₀ approximately 70 nM (Ramsay 2007, Biochem Pharmacol). Co-administration with SSRIs, SNRIs, tricyclic antidepressants, MAOIs, triptans, linezolid, or other serotonergic agents has produced serotonin syndrome, including fatal cases in the perioperative parathyroid-surgery literature (Ng 2008, Anaesth Intensive Care). The FDA issued a Drug Safety Communication on July 26, 2011 and reaffirmed it in the Provayblue 2024 label revision: discontinue serotonergic agents before elective methylene blue administration and monitor for serotonin syndrome if urgent use is required.
In plain English
It blocks an enzyme that processes serotonin — which is why mixing it with antidepressants is dangerous
Methylene blue strongly blocks an enzyme called MAO-A — the same enzyme targeted by old-fashioned MAO-inhibitor antidepressants. That means combining methylene blue with common antidepressants (Zoloft, Lexapro, Effexor, tricyclics, MAOIs), migraine triptans, or the antibiotic linezolid can cause serotonin syndrome — a dangerous, sometimes fatal buildup of serotonin. Multiple deaths have been reported, including during parathyroid surgeries where methylene blue was used as a dye. The FDA issued a formal warning on July 26, 2011 and reaffirmed it in the 2024 Provayblue label update: stop the antidepressant first if possible; if not possible, watch closely for serotonin syndrome.
- 06
What is NOT established about the mechanism
The hormetic dose-response curve is documented in cell culture but has not been resolved into a defensible oral dosing protocol in humans. Human pharmacokinetics show roughly 70% oral bioavailability with a terminal half-life of 5–6 hours (Peter 2000), but tissue distribution — particularly brain concentration achieved at the doses used in wellness protocols (typically 10–50 mg oral) — is not well-characterized. Whether any OTC oral dose achieves the sub-micromolar intramitochondrial concentration required for the electron-carrier benefit in human brain tissue is not known.
In plain English
What we still don't know
The "just right" dose window has been mapped in cell cultures, but not in humans — nobody has figured out an oral dose that reliably delivers the sweet-spot concentration to the brain. We know about 70% of an oral dose reaches the bloodstream and it hangs around about 5–6 hours. But how much actually makes it into brain mitochondria at the 10–50 mg doses most wellness users take is unknown. Whether those doses even reach the concentration needed for the supposed brain benefit has never been proven.